Results 211 to 220 of about 136,538 (301)

Outcomes in Recurrent Focal Segmental Glomerulosclerosis Post‐Kidney Transplantation Treated With Therapeutic Plasma Exchange: A Retrospective Cohort Study

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Recurrence of focal segmental glomerulosclerosis (FSGS) following kidney transplantation remains a significant cause of allograft loss. Much remains unknown about the efficacy of apheresis treatments and the factors that determine favorable treatment outcomes.
Chimezie Godswill Okwuonu, Muzamil Olamide Hassan, Olalekan Eziekel Ojo, Sarthak Virmani, Rasheed Abiodun Balogun   +4 more
wiley   +1 more source

Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Sarcopenia is a major contributor to frailty and mortality in ageing and obesity and is tightly linked to metabolic dysfunction. Imeglimin is a first‐in‐class oral hypoglycaemic agent targeting mitochondrial function; however, despite the central role of mitochondria in skeletal muscle homeostasis, its effects on skeletal muscle ...
Yangli Ye, Diandian Qian, Ikumi Nomura, Naoki Kobayashi, Yukiko Shimizu, Tadashi Okamura, Motoharu Awazawa, Kohjiro Ueki   +7 more
wiley   +1 more source

Beyond Fibrinolysis: Urokinase Plasminogen Activator as an Early Regulator of Obesity. [PDF]

Arterioscler Thromb Vasc Biol
Torrente D, Strickland S.
europepmc   +1 more source

Metabolic Regulation of Macrophages in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang, Yu Zhang, Jiali Min, Jiahui Yang, Yuchen Li, Hao Zhang, Shanshan Liu   +6 more
wiley   +1 more source

Toward improved thrombolysis in ischemic stroke: targeting nonfibrin components. [PDF]

Res Pract Thromb Haemost
De Meyer SF.
europepmc   +1 more source

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source

Association of VTN Genotype with Plasminogen Activator Inhibitor-1 Activity in Late-Onset Alzheimer's Disease. [PDF]

Genes (Basel)
Agirbasli D, Agirbasli M, Cakir ME, Muftuoglu M.   +3 more
europepmc   +1 more source

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older‐Age Bipolar Disorder ISBD Task Forces

Bipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Background Cognitive impairment is common in bipolar disorder (BD), but the underlying pathophysiology remains unclear. This systematic review aimed to (1) summarize all literature describing relationships of biofluid biomarkers and cognition in BD and (2) identify which biofluid biomarkers correlate most consistently with cognition in BD ...
Alexandra J. M. Beunders, Sigfried N. T. M. Schouws, Andrew T. Olagunju, Vicent Balanzá‐Martínez, Nicole C. M. Korten, Ralph W. Kupka, Katherine E. Burdick, Andre F. Carvalho, Ariel G. Gildengers, Lars V. Kessing, Roger S. McIntyre, Paula V. Nunes, Ayal Schaffer, Ivan J. Torres, Shang‐Ying Tsai, Tamsyn E. Van Rheenen, Eduard Vieta, Lakshmi N. Yatham, Allan H. Young, Lisa T. Eyler, Kamilla W. Miskowiak, Annemiek Dols   +21 more
wiley   +1 more source

Leptospira glyceraldehyde-3-phosphate dehydrogenase (LiGAPDH): a cell-surface plasminogen binding protein. [PDF]

FEMS Microbiol Lett
de Souza MCL, Nepomuceno R, Santos CM, Abe CM, Barbosa AS.   +4 more
europepmc   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source